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Abstract
Background: The higher specificity of amino-acid positron emission tomography (AA-PET) in the diagnosis of
gliomas, as well as in the differentiation between recurrence and treatment-related alterations, in comparison to
contrast enhancement in T1-weighted MRI was demonstrated in many studies and is the rationale for their
implementation into radiation oncology treatment planning. Several clinical trials have demonstrated the
significant differences between AA-PET and standard MRI concerning the definition of the gross tumor volume
(GTV). A small single-center non-randomized prospective study in patients with recurrent high grade gliomas
treated with stereotactic fractionated radiotherapy (SFRT) showed a significant improvement in survival when
AA-PET was integrated in target volume delineation, in comparison to patients treated based on CT/MRI alone.
Methods: This protocol describes a prospective, open label, randomized, multi-center phase II trial designed to
test if radiotherapy target volume delineation based on FET-PET leads to improvement in progression free survival (PFS)
in patients with recurrent glioblastoma (GBM) treated with re-irradiation, compared to target volume delineation based
on T1Gd-MRI. The target sample size is 200 randomized patients with a 1:1 allocation ratio to both arms. The primary
endpoint (PFS) is determined by serial MRI scans, supplemented by AA-PET-scans and/or biopsy/surgery if suspicious
of progression. Secondary endpoints include overall survival (OS), locally controlled survival (time to local progression
or death), volumetric assessment of GTV delineated by either method, topography of progression in relation to MRI-
or PET-derived target volumes, rate of long term survivors (>1 year), localization of necrosis after re-irradiation, quality
of life (QoL) assessed by the EORTC QLQ-C15 PAL questionnaire, evaluation of safety of FET-application in AA-PET
imaging and toxicity of re-irradiation.
Discussion: This is a protocol of a randomized phase II trial designed to test a new strategy of radiotherapy target
volume delineation for improving the outcome of patients with recurrent GBM. Moreover, the trial will help to develop a
standardized methodology for the integration of AA-PET and other imaging biomarkers in radiation treatment planning.
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Background
During the last years enormous progress has been made
in the area of high precision radiotherapy [1]. In the
brain it is now technically feasible to irradiate complex
target volumes with a precision of less than 1 mm, while
sparing normal tissues [2]. This offers the opportunity to
significantly escalate the radiation dose for the tumor
tissue, which is considered to be a key for increasing
local control rates. However, the potential of high preci-
sion radiotherapy can only be realized when the tumor
volume can be accurately delineated by imaging tech-
niques [3]. Studies have shown that standard anatomic
imaging modalities (CT, MRI), while very accurate at
visualizing normal anatomical structures, are limited in
defining tumor extension for radiation treatment plan-
ning [4]. Traditionally, the target volume definition for
irradiation, as well as re-irradiation after recurrence, of
malignant gliomas is based on T1-weighted MRI with
Gadolinium (Gd) [5]. Contrast enhancement is a conse-
quence of disruption of the blood-brain barrier (BBB)
which does not necessarily reflect the real tumor exten-
sion in gliomas. Gross tumor mass has been detected
beyond the margins of contrast enhancement, in the sur-
rounding edema and even in the adjacent normal-
appearing brain tissue [6–10].
After therapy (surgery, irradiation and/or chemotherapy),
BBB disturbances can frequently be treatment-related (for
example associated with postoperative granulation or radi-
ation necrosis) and cannot be differentiated from persistent
tumor on conventional MRI [9]. This phenomenom was
termed “pseudoprogression” [11] and, in this case non-
tumoral tissue may be erroneously included in the gross
tumor volume (GTV), leading to a higher rate of sides ef-
fects after re-irradiation. Vice versa, after systemic treat-
ment with vascular endothelial growth factor (VEGF)
receptor signalling pathway inhibitors such as bevacizumab,
“pseudoresponse” has been described [11–13].
In patients that have been previously irradiated, the
volume of normal tissue included in high dose areas
should be as small as possible [14] to avoid severe toxic-
ities, such as radiation necrosis [15]. Therefore, the tar-
get volume has to encompass mainly the macroscopic
tumor mass (GTV) without including a large area of
suspected microscopic tumor infiltration (clinical target
volume, CTV). The margins of the planning target vol-
ume (PTV) have to be very small, in order to spare
normal brain tissue. High conformal radiation strategies
like stereotactic-fractionated radiotherapy (SFRT), image-
guided radiotherapy (IGRT) and intensity modulated radio-
therapy (IMRT) are used to focus the irradiation on the
gross tumor mass and reduce the required margin, making
GTV delineation in this case a major issue [9, 16, 17].
For high precision radiotherapy, inaccuracies in tumor
delineation may offset any gain in local control rates
achieved by dose escalation, emphasizing the need for
new imaging approaches to increase tumor delineation
for high precision radiotherapy [18].
Along this line, imaging the biological and molecular
characteristics of the tumor tissue by positron emission
tomography (PET) is an interesting approach to improve
treatment planning for high precision radiotherapy. Mul-
tiple studies correlating imaging findings with histo-
pathological evaluation in surgically treated patients
with high grade glioma have indicated that molecular
imaging with amino acid (AA) PET (L-[methyl-11C]methio-
nine (MET) or O-(2-[18F]fluoroethyl)-L-tyrosine (FET)) is
more specific and equally sensitive for tumor staging than
MRI [4, 19]. Based on these data, the infrastructure for AA-
PET imaging has become widely available in major hospi-
tals [20]. Although AA-PET imaging shows great promise
for target delineation, it has not been rigorously evaluated
in clinical trials. Several studies in patients with gliomas
have indicated that PET based target volumes differ mark-
edly from target volumes defined by MRI, but the method-
ology for tumor delineation on PET images differs
significantly among these studies [8, 21–28]. More import-
antly, there are no randomized trials that have evaluated
the impact of PET based radiotherapy on patient outcome.
According to relevant clinical trial registers, no clinical trials
are currently running or planned for this indication (http://
www.drks.de, http://www.controlled-trials.com, http://clini
caltrials.gov, http://www.who.int/ictrp; last accessed on
07.05.2016). Generally, imaging techniques have so far not
been evaluated with the same rigor as therapeutic agents.
The high costs associated with modern imaging techniques
make it necessary to use a similar approach as for evalu-
ation of new therapeutic agents.
The hypothesis of the study is that AA-PET, having a
higher specificity and equal sensitivity for tumor tissue
in comparison to MRI (T1 with gadolinium), will
visualize the tumor mass with a higher precision and
thus will improve patient outcome. This hypothesis was
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pre-tested in a previous small prospective monocentric
non-randomized pilot study led by the principal investi-
gators [9]. In this cohort of 44 patients, a statistically sig-
nificant better survival time was reported in patients
with recurrent gliomas treated with re-irradiation using
SFRT based on AA-PET in comparison to the same ir-
radiation regime based on T1Gd-MRI on univariate ana-
lysis. The goal of this trial is to verify the improved
outcome for patients in a randomized multicenter phase
II study with progression free survival (PFS) as the pri-
mary endpoint to specifically address the potential im-
pact of the differences in radiation target volumes. The
results of this trial could have a significant impact not
only on GTV delineation in recurrent GBM, but also in
the tumor mass delineation of primary tumors, in the
evaluation of tumor response and treatment monitoring
and in developing of a standardized methodology for tar-
get volume delineation based on PET. A further goal of
the study is to establish a framework for the use of mo-
lecular imaging in radiation oncology.
Methods/design
Trial design and setting
This is a prospective, open label randomized (allocation 1:1)
two-arm parallel group phase II multi-centre trial designed
to test for differences in the impact of an FET-PET-based
(experimental, Arm A) versus a T1Gd-MRI-based (control,
Arm B) treatment planning on the progression-free survival
in patients with recurrent GBM treated with re-irradiation.
Trial sites are academic hospitals and community
clinics located in Aachen, Bonn, Dessau, Erlangen, Freiburg,
Hannover (two sites), Karlsruhe, Köln, Magdeburg,
Mannheim, Marburg, München, Offenburg, Rostock,
Stuttgart, Trier, and Tübingen.
The trial was approved by the ethics committee of the
University of Freiburg (EK-Freiburg 133/10) and by the
local ethics committees of participating sites. The
GLIAA trial has been thoroughly examined and ap-
proved by the Federal Office for Radiation Protection
(Bundesamt für Strahlenschutz, BfS) and the Federal
Institute for Drugs and Medical Devices (Bundesamt für
Arzneimittel und Medizinprodukte, BfArM). Written in-
formed consent for study participation is obtained from
all patients before the initiation of any study-specific
procedures. The GLIAA trial is associated with the
German Neurooncological Network (Neuroonkologische
Arbeitsgemeinschaft, NOA-10) and Working Group
Radiation Oncology (Arbeitsgemeinschaft Radiologische
Onkologie, ARO2013-1) of the German Cancer Society
(Deutsche Krebsgesellschaft, DKG).
Study population
The target population for this trial is previously irradi-
ated patients with recurrent GBM. For the proposed
trial, there is no gender requirement. No gender ratio
has been stipulated in this study as the results of the
preclinical and/or clinical studies did not indicate any
difference in the effect of the study treatment in terms
of efficacy and safety. No healthy persons will be in-
cluded. To avoid selection bias, investigators should en-
roll patients irrespectively of whether or not any
differences are seen in GTV-delineation based on FET-
PET versus T1Gd-MRI.
Key inclusion criteria at the time of randomization are:
(1) Patient’s written informed consent (IC) obtained
latest the day after FET-PET acquisition, (2) legal cap-
acity: Patient is able to understand the nature, signifi-
cance and consequences of the study, (3) age ≥ 18 years
(no upper limit of age), (4) Karnofsky Performance Score
(KPS) > 60 %, (5) registration in the electronic case re-
port form, (6) recurrence of GBM (WHO grade IV) and
either not eligible for tumor resection or with macro-
scopic residual tumor after resection of the recurrent
GBM, (7) histological confirmation of GBM at initial or
secondary diagnosis, (8) previous radiation therapy of
high grade glioma (WHO Grad III or IV) with a total
dose of 59.4 - 60Gy (single dose 1.8 – 2.0 Gy), (9) at
least 6 months between the end of pre-irradiation and
randomization, (10) recurrent tumor visible on FET-PET
and T1Gd-MRI with the maximum diameter measuring
1 cm to 6 cm by either technique (in case of multifocal
tumor, the sum of all diameters has to be 1-6 cm on
FET-PET and T1Gd-MRI), (11) target volume definition
possible according to both study arms, (12) start of re-
irradiation planned within 2 weeks from FET-PET and
MRI. Key Exclusion criteria are: (1) Recent (≤ 4 weeks be-
fore IC) histological result showing no tumor recurrence,
(2) previous treatment of GBM with bevacizumab or other
molecular targeted therapies less than 6 months before
MRI and FET-PET used for radiotherapy planning, (3)
technical impossibility to use MRI or FET-PET dataset for
RT planning, (4) less than 2 weeks between the last day of
last chemotherapy given and planned start of reirradiation,
(5) less than 3 weeks between resection of recurrent GBM
and planned start of re-irradiation, (6) chemotherapy or
molecular targeted therapies planned during re-irradiation,
(7) additional chemotherapy or molecular targeted therapy
or further surgery planned before diagnosis of further
tumor progression after study intervention, (8) simultan-
eous participation in other interventional trials which could
interfere with this trial and/or participation in a clinical trial
within the last thirty days before the start of this study and/
or previous participation (randomization) in this study, (9)
pregnancy, nursing, or patient not willing to prevent a
pregnancy during treatment, (10) known or persistent
abuse of medication, drugs or alcohol, (11) known al-
lergy against the MRI contrast agent Gadolinium or the
PET tracer 18F-FET or against any of the components.
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Study treatment and procedures
The trial randomizes the patients to the following two
treatment arms with a 1:1 allocation ratio: In the control
intervention, the MRI based GTV delineation will be
performed with respect only to the T1Gd-MRI image
dataset. Here, the GTV is defined as the tumor related
contrast enhancement with no safety margin in accord-
ance with a neuroradiologist. In the experimental arm,
the PET based GTV delineation will employ FET uptake
with a greater value than 1.8 +/- 0.1 times of normal
brain tissue uptake as a starting point, visually verified
and modified by an experienced nuclear medicine spe-
cialist together with the treating radiation oncologist. To
define the acquisition protocol and reconstruction pa-
rameters for each participating study centre, PET/CT
scanner phantom studies will be performed. Freiburg
will be the reference centre.
Starting from the GTV, for both target volumes (MRI
and FET-PET based), a CTV will be defined by adding
3 mm in either direction respecting anatomical boundar-
ies like skull and/or tentorium. This CTV will then be ex-
panded to the PTV by adding 1–2 mm in all directions.
Radiotherapy planning will be performed after
randomization using the predefined target volume for
the treatment arm allocated. In both study arms, pa-
tients will be given a high-precision re-irradiation
with a total dose 39 Gy, 3 Gy/d, 5×/week to the PTV
as defined according to the respective study arm. The
dose specification will be according to the criteria of
the International Commission on Radiation Units and
Measurements (ICRU) with the 95 % isodose sur-
rounding the PTV.
In both treatment arms, the MRI/CT based contouring
of risk organs will be done after the definition of the GTV.
The following constraints for normal tissue/organs at risk
have to be respected in radiotherapy planning, which re-
late to the cumulative doses from the actual and the prior
radiation treatment in the same irradiated point / area,
calculated by the equivalent dose in 2 Gy fractions (EQD2,
α/β = 2 Gy): (1) The maximum total dose to the optical
chiasm and/or both optical nerves must not exceed 54 Gy,
(2) if only one optical nerve is involved, the maximum
dose must not exceed 60 Gy, (3) the maximum dose to
the brain stem must not exceed 66 Gy in 10 % of volume,
(4) the medulla oblongata must not receive more than
60 Gy at maximum point, (5) the maximum dose to the
retina must not exceed 54 Gy.
Irradiation is given either as SFRT using an external
coordinate system and/or IGRT with CT and/or kV im-
aging of the treatment position before every treatment
fraction. The mean positioning tolerance of all fractions
as documented by this imaging must be ≤ 2 mm.
The flowchart of the treatment and follow-up schedule
is shown in Fig. 1.
Quality assurance for radiation treatment planning
After completion of radiotherapy planning for the first
study patient, the study centers will upload the pseudony-
mized PET, CT and MRI images well as the pseudonymized
radiotherapy treatment plan on a dedicated web-platform.
A review committee including a radiation oncologist, a
nuclear medicine physician and a physicist in the coordinat-
ing study centre in Freiburg will check the key parameters
of imaging and treatment planning before the initiation of
radiotherapy of the second study patient. After passing
quality assurance for the at least one patient, further im-
aging and RT planning will undergo mutual monitoring by
the members of the study group in the framework of regu-
lar study group meetings.
Fig. 1 Flowchart of the GLIAA trial. AA-PET = amino acid positron emission tomography; MRI =magnetic resonance imaging; FET =O-(2-[18F]fluoroethyl)-L-
tyrosine; Gd = gadolinium
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Study endpoints
The primary endpoint is PFS, defined as time from
randomization until tumor progression or death. Pro-
gression is determined based on MRI and confirmed by
AA-PET and/or positive biopsy/surgery as follows. A
tumor-suspicious lesion on MRI according to RANO
criteria [29] which is confirmed by AA-PET and/or bi-
opsy/surgery is considered as tumor progression, while a
negative PET-scan will exclude progression. A positive
PET scan, if unclear, should be followed by biopsy.
Patients receiving any new treatment (chemotherapy or
immunotherapy) for progression of their GBM in the ab-
sence of diagnosed tumor progression, and patients re-
ceiving surgery for distant progression or receiving
bevacizumab for a radionecrosis will also be considered
as having an event for the endpoint PFS, at the date that
treatment was initiated.
Secondary endpoints are the following. (1) Overall
survival (OS) is defined as time from randomization to
death. (2) Volumetric assessment of GTV based on
PET and MRI is based on PET/MRI + RT-structure set
image co-registration. The relation of both GTVs to
each other, especially overlap and non-overlap volumes,
will be assessed. (3) The topography of progression
after re-irradiation will be evaluated at the time of pro-
gression. In all available image datasets, the topograph-
ical relation of the tumor re-growth will be scored as
local progression or distant progression: Local progres-
sion will be determined as in field progression (largest
proportion within the PTV), or margin progression
(largest proportion within 2 cm and located in the same
anatomical region as the PTV); Distant progression will
be determined as outfield progression (largest proportion
clearly [>2 cm] outside of PTV or located in another ana-
tomical region). Progression will be judged as either in
PET/MRI-GTV, marginal to PET/MRI-GTV, or clearly
outside PET/MRI-GTV, both for PET and MRI, respect-
ively. (4) Locally controlled survival is defined as time
from randomization to local progression (see 3) or death.
(5) Long term survival is defined as OS > 1 year. (6) The
topography of necrosis after re-irradiation will be deter-
mined with respect to the irradiated volume (PTV) as de-
scribed above. (6) Quality of life (QoL) will be determined
using the EORTC QLQ-C15 PAL questionnaire [30]
which is especially aimed to patients in a (near) palliative
care setting. The primary scale for the QoL evaluation is
the global health status/QoL scale status. The other scales
and single items are secondary outcomes. The primary
outcome measure is the change from baseline before radi-
ation therapy to follow up measurements. (7) A possible
impact of diffusion/perfusion and FLAIR MRI on target
volume delineation will be analyzed optionally in depart-
ments having the technology and the know-how for these
investigations. These evaluations will be handled as a
separate subproject, to be described elsewhere. (8)
Adverse events occurring until incl. day 7 after FET-PET
imaging are registered to address safety of FET-PET im-
aging. (9) Occurrence of a range of pre-specified adverse
events (AEs) considered as possible radiotherapy treat-
ment toxicity is registered and documented according to
NCI CTCAE v4.03 (http://evs.nci.nih.gov/ftp1/CTCAE/
CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf) dur-
ing treatment and follow up. Events occurring more than
90 days after the start of irradiation are considered as late
toxicity. In addition, we register serious adverse events
(SAEs) occurring from start of radiotherapy until 30 days
after end of radiotherapy as well as SAEs occurring during
the complete follow up period which are considered as re-
lated to radiotherapy.
Sample size
The number of patients to recruit to this phase II study
is derived from the primary endpoint PFS. Based on data
from a literature report [31], where 6-months PFS
ranged between 28 and 39 %, and considering that this
study includes also patients with larger tumors up to a
diameter of 6 cm, we expect 30 % PFS at 6 months in
the control arm. The objective is to detect a difference if
the experimental treatment entails an increase of at least
15 % in the 6-months PFS rate. Such an improvement
seems feasible, since OS in the pilot study was 5 months
in the control arm (treated based on MRI) versus
9.5 months in the experimental arm (treated based on
PET/SPECT) [9]. Assuming exponentially distributed
PFS times, the target difference of a 15 % increase to
45 % 6-months PFS corresponds to a hazard ratio (HR)
of 0.667 for the experimental versus the control group
(median ratio of 1.5).
The study was planned under these assumptions, using
the comparative phase II design with one-sided type I
error rate α = 10 and 90 % power proposed by Korn et
al. [32], and a group sequential plan with one interim
analysis during the recruitment phase, with the option
to stop the trial early for futility. Assuming a constant
recruitment rate, the following procedure to test the null
hypothesis H0: HR ≥ 1.0 against the alternative hypoth-
esis of superiority in the experimental arm, H1: HR < 1.0,
has the desired properties (SAS Version 9.2, proc sequ
design): After recruitment of 115 patients over a period
of 15 months, the trial is to be stopped for futility
(accept H0) if the p-value of the one-sided log-rank test
of H0 versus H1 is above 0.51742. Otherwise, recruit-
ment is to continue for another 9 months up to a total
of 184 patients over a total period of 24 months, with
additional follow up for 12 months. At the final analysis
after 36 months, a log-rank test of H0 versus H1 at one-
sided nominal level of α = 10 % is performed. With this
sequential plan, the entire procedure, accounting for the
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interim analysis, has a power of 90 % and a type I error
rate of 9.252 %. If H1 is true, the probability to stop for
futility is 3.021 %. Under H1, the expected number of
events is 71.85 at 15 months and 176.22 at 36 months.
To compensate for possible losses to follow up or ineli-
gible patients, a target number of 200 randomizations
over a period of 24 months was planned, and the interim
analysis should be performed when 125 = 200 × 15/24)
patients would be randomized.
Randomization
Central randomization is performed by means of the
minimization technique with a random element as ini-
tially described by Pocock and Simon [33], using a
computerized randomizer tool (https://www.randomi-
zer.at/) with the following factors in the minimization
algorithm: (1) time since first radiation treatment, cal-
culated between the last day of previous irradiation and
randomization (≤14 months vs. >14 months) (2) previous
chemotherapy treatment (≤ 7 cycles of TMZ vs. > 7 cycles)
(3) maximum tumor diameter on MRI (GTV ≤ 3 cm vs.
GTV > 3 cm) (4) MGMT-status (methylated vs. non-
methylated vs. not yet determined). An open label design
was chosen because effective blinding was considered
unfeasible. However, the randomization procedure guar-
antees concealment of treatment allocation und thus min-
imizes selection bias.
Statistical analysis
Because this is a phase II study, the primary analyses of
the efficacy endpoints PFS, locally controlled survival
and OS will be performed in the per protocol popula-
tion, which comprises all eligible patients who started
their allocated treatment (at least one radiotherapy frac-
tion as randomized). Sensitivity analyses according to
intention-to-treat will include all patients as randomized.
Patients free from progression and alive at the last visit
will be censored for PFS at the day of last assessment.
Patients free from in-field and margin progression and
alive at the last visit will be censored for locally con-
trolled survival at the day of last assessment. Patients
not known to have died during the study will be cen-
sored for OS at the day they were last known to be alive.
The primary comparison of the time-to-event distribu-
tions between the two treatment arms will be done using
the one-sided log-rank test at significance level α = 10 %
stratified by all factors used for randomization, to test
H0: HR ≥ 1.0 versus H1: HR < 1.0. The HR for the experi-
mental versus the control arm and its two-sided 80 and
95 % confidence intervals will be estimated using a Cox
proportional hazards model stratified by the same fac-
tors. Distributions of PFS, locally controlled survival and
OS will be estimated by the Kaplan-Meier method. The
PFS and locally controlled survival rates at six months,
the OS rates at one year, and medians of PFS, locally
controlled survival and OS will be presented with two-
sided 95 % confidence interval computed using the log-
log transformation [34]. Additional exploratory analyses
will study the prognostic impact of factors other than
treatment, including age, sex and MGMT status.
Exploratory QoL analyses in the per protocol popula-
tion will evaluate the evolution of QoL over time in the
group of patients still alive at the respective time
points. The results will be interpreted in conjunction
with Kaplan-Meier estimates for OS. Cross-sectional
descriptions of the average scores, which range from 0
to 100, will be presented by treatment arm with confi-
dence intervals. Missing values will be imputed via lin-
ear regression models to assess the stability of the
results. The primary analyses will classify the change
scores according to the established minimal clinically
important difference of 10 points [35] as (a) worsening
vs unimportant worsening or improvement and (b) im-
provement vs unimportant improvement or worsening.
Analyses of the safety of FET application are per-
formed in the pharmacovigilance population of all pa-
tients who received FET. Analyses of radiotherapy
treatment toxicity are performed in the safety population
of all patients who started treatment (at least one radio-
therapy fraction), irrespective of eligibility, according to
the treatment arm that they started. Rates of AEs occur-
ring until incl. day 7 after FET-PET imaging and of SAEs
occurring from start of radiotherapy until 30 days after
end of radiotherapy will be presented with exact two-
sided 95 % confidence intervals. Further analyses of
treatment toxicity will present the worst grade of acute/
subacute and late side effect by treatment arm. The time
to occurrence of any severe (NCI-CTC grade ≥3) side ef-
fects and to any severe late side effects will be estimated
by cumulative incidence. The time to severe (late) side
effects will be calculated from the time of start of radi-
ation treatment to the first evidence of any grade 3 (late)
side effects. Patients alive without grade 3 (late) toxicity
will be censored at the date of last follow-up, patients
who died without experiencing (late) grade 3 side effects
will be assessed as competing risk at the time of death.
Interim analyses
Initially, a first interim analysis comparing the GTV de-
lineated according to FET uptake with the GTV delin-
eated according to Gd enhancement in T1-weighted
MRI was planned with the aim to stop the trial early for
futility if the delineation would not show a difference in
target volumes in a sufficient number of patients. How-
ever, in the meantime a monocenter feasibility study
(German Clinical Trials Registry DRKS00000633) was
started, and the protocol of the present multicenter trial
was updated. It was decided that if the feasibility study
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would show relevant PET/MRI-GTV non-overlap in a
substantial proportion of patients (> 25 %), the first
interim analysis of the present multicenter trial would
be cancelled. The results of the feasibility study have
turned out as expected, so that the interim analysis of
GTVs in the present trial will not be performed (un-
published data).
A second interim analysis is planned with the aim to
stop the trial early for futility if the experimental arm
shows no favourable trend in terms of the trial primary
endpoint PFS. It will be performed in the per protocol
population when the first 125 patients have been ran-
domized, which was initially expected to occur at
month 15 from study start. The test will be carried out
as described in the paragraph on sample size. The trial
will be stopped for futility (accept H0) if the p-value is
above 0.51742.
Additionally, the rate of patients registered but not
randomized to the study is regularly monitored descrip-
tively during the recruitment phase. The aim is to assess
the true feasibility of the study and to allow for correct-
ive measures if there is a selection bias towards patients
with large volumes or big differences in volumes not
being randomized.
Discussion
The goal of this study is to evaluate if the delineation
of the target volume based on AA-PET could have an
impact on the clinical outcome in patients with re-
current gliomas treated with 3D-high conformal re-
irradiation.
The selection of this disease is based on several con-
siderations. First of all, treatment of recurrent GBM is
an unsolved clinical problem and the prognosis of pa-
tients has remained poor despite intense research [36].
Thus, new treatment approaches including re-irradiation
are urgently needed [37]. Second, local recurrence after
surgery and radiotherapy is the cause of disease progres-
sion in almost all patients. Therefore, the impact of a
local treatment approach with high precision radiother-
apy on patient survival is expected to be higher than for
other malignant diseases, which also or predominantly
recur systemically [38]. Combined with the poor progno-
sis of recurrent GBM, this means that the impact of mo-
lecular imaging on patient outcome can be studied in a
relatively small patient population and with a relatively
short follow-up period. Third, in patients treated with
re-irradiation the dose should be focused on the GTV,
sparing the normal brain tissue as much as possible [14].
The treatment should be performed using high-
precision radiation therapy, which is able to focus the
dose on the macroscopic tumor mass and to spare the
normal brain tissue [2]. The accuracy in the GTV defin-
ition should have a significant impact on local tumor
control and should translate into improved clinical out-
come [9]. Forth, there is considerable evidence that
current approaches for target delineation in recurrent
GBM are limited due to unspecific treatment related
changes seen on CT and MRI [4]. Fifth, there is substan-
tial data that PET imaging with radiolabeled amino acids
provides more accurate information about tumor exten-
sion than MRI or CT, especially after pretreatment [39].
Sixth, the reported differences in tumor extension ob-
served between MRI and AA-PET, the so-called non-
overlap volume of the GTVs, are significant and appear
robust enough to be tested in a multicenter clinical trial
[8 and unpublished data from a monocentric feasibility
study]. The magnitude of the differences between AA-
PET and MRI also makes it clinically highly relevant to
test AA-PET based radiation treatment planning in a
clinical trial. Considering the reported high sensitivity
and specificity of AA-PET for detection of recurrent
GBM and the large differences in tumor extension be-
tween PET and MRI observed in patients scheduled to
undergo radiotherapy, there appears to be a high risk
that large parts of the tumor mass are missed when
radiotherapy is based on the findings on MRI only.
Finally, in preparation of this randomized multicenter
trial, the principal investigators performed a small
monocenter non-randomized study showing that sur-
vival is significantly improved when AA-PET is imple-
mented into radiation treatment planning [9].
Taken together, considering that in patients treated
with re-irradiation we will focus the dose on the GTV,
using very small margins to CTV and PTV, we consider
that this is a valid clinical model for demonstrating the
differences between AA-PET and T1-Gd-MRI in the
visualization of GTV, and the consequences on the clin-
ical outcome. As outlined above, we believe that recur-
rent GBM represents an ideal model to study the impact
of molecular imaging on patient management in a ran-
domized clinical trial.
Furthermore, the lessons from this study could also
be extrapolated to primary gliomas. The results could
have a significant impact on tumor mass detection,
treatment planning (surgery, radiation therapy, chemo-
therapy, immunotherapy, gene-virotherapy which needs
to be directed towards active tumor areas, etc.). An ac-
curate visualization of tumor mass will have a signifi-
cant impact on the evaluation of tumor response after
treatment and on treatment monitoring and could lead
to a “modified Response Evaluation Criteria In Solid
Tumors (RECIST)” or RANO definition adapted for
PET imaging in neurooncology.
Therefore, we consider that the results of this study
could change significantly the treatment strategy in brain
tumors, if in addition confirmed in a phase III trial. An-
other important goal of this trial is to develop a strategy
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for GTV delineation based on PET. Considering the in-
creasing impact of PET in radiation treatment planning,
we consider that our trial will have a significant impact on
the development of systematic strategies for tumor delin-
eation based on PET. The lessons from this study will be
generally useful for the development of a biological based
treatment planning, also for other tumor entities. Add-
itionally, in the context of the pharmacovigilance aspects
of this study, the safety of FET application in clinical rou-
tine as AA-PET-tracer will be evaluated.
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